NAFLD: Review of Management for Primary Care Providers
The authors considered NAFLD evaluation, diagnosis, and management in the primary care setting and endocrinology clinics.
Search Results for Fibrosis
Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic fatty liver disease (NAFLD) with lessons from cohort studies and placebo arms of trials. The take home points are that the natural history of NAFLD is variable
NAFL: FIB-4, a strong predictor of both all-cause mortality and liver-related adverse outcomes
The authors analysed data on 30 million patients categorised into three diagnostic groups: NAFLD, NASH, and at risk of NASH.
PPAR’S AS CRITICAL REGULATORS OF METABOLISM
The prevalence of NAFLD is increasing worldwide in parallel with the rising epidemics of obesity and T2DM. NASH is now becoming one of the main causes of Cirrhosis and HCC and the main indication for liver transplantation. Except for lifestyle modification through diet and exercise, there are currently no approved treatments for NASH. While bariatric surgery can be considered in otherwise eligible patients with NAFLD or NASH, it is premature to consider it as an established option for the treatment of NASH. Numerous novel treatments for NASH are currently in development targeting metabolism, cell death, inflammation, fibrosis and the gut-liver axis. However, drugs focusing on just one target may not be sufficiently efficacious and might have to be used in combination. That being said, Pan-PPAR agonists that act on multiple targets may be a promising new therapeutic option for NASH.
B cells aggravate NASH: an innate and adaptive signalling
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B cells with elevated pro-inflammatory cytokine secretion .....
NAFLD: from drivers to targets
In this review, A. Santos-Laso et al. (Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute, Santander, Spain) summarise the key aspects of NAFLD .....
Author – Nash Experts
Discover our Trusted Global Independent Medical and Scientific Experts. Uncover the latest advancements in NASH research and treatment from leading hepatology experts.
NASH Treatment: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a focus on the pathogenesis of NASH and the different pathways on how underlying steatohepatitis is developed, he presents his expert perspective on how patient outcomes can be improved.
Identify the risk of NASH and cirrhosis: the time to screen is now
Early screening and risk stratification for advanced liver fibrosis is critical in primary care and endocrinology clinics to prevent future cirrhosis in groups.....
Role of age, gender and ethnicity in the association between visceral adiposity index and non-alcoholic fatty liver disease among US adults (NHANES 2003-2018): cross-sectional study
In this cross-sectional population-based study, the authors aimed to explore the association between visceral adiposity index and NAFLD in the general US.....
Accuracy of serum biomarkers versus liver biopsy
This first study on Croatian patients with NAFLD was conducted to evaluate the diagnostic performance of various biomarkers for steatosis, fibrosis, and inflammation in comparison to a liver biopsy.....
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of non-alcoholic fatty liver disease, NAFLD.